Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Treatment Of Oat Cell Carcinoma Of The Lung: Complete Remissions, Acceptable Complications, And Improved Survival

F. A. Greco, R. L. Richardson, S. F. Schulman, S. Stroup and R. K. Oldham
The British Medical Journal
Vol. 2, No. 6129 (Jul. 1, 1978), pp. 10-11
Published by: BMJ
Stable URL: http://www.jstor.org/stable/25428066
Page Count: 2
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Preview not available

Abstract

Oat cell lung cancer is a common disease which is usually disseminated by the time it is diagnosed. Treatment with cyclic combination chemotherapy (cyclophosphamide, doxorubicin, vincristine) administered concurrently with radiotherapy to the chest lesion and subsequent prophylactic brain irradiation was investigated in 36 patients with oat-cell carcinoma of the lung. Complete remissions occurred in 26 of the patients (15 of the 16 with limited-stage disease and 11 of the 20 with extensive-stage disease). Symptomatic improvement occurred in all patients. Twelve of the 16 patients with limited disease remained well and free of disease for over a year. The results were equivalent to those of a similar though more intensive regimen, but the toxicity was much less (there were no treatment-related deaths). Transient granulocytopenia with the risk of infection was the most serious complication. Survival and quality of life have been improved for all patients, particularly those with limited disease, who have previously responded poorly to treatment.

Page Thumbnails

  • Thumbnail: Page 
10
    10
  • Thumbnail: Page 
11
    11